Compile Data Set for Download or QSAR
maximum 50k data
Found 38 with Last Name = 'kaneko' and Initial = 'o'
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148155(US8962612, 26)
Affinity DataKi:  0.680nM ΔG°:  -54.4kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148163(US8962612, 66)
Affinity DataKi:  0.75nM ΔG°:  -54.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148169(US8962612, 80)
Affinity DataKi:  0.850nM ΔG°:  -53.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148165(US8962612, 74)
Affinity DataKi:  0.880nM ΔG°:  -53.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148171(US8962612, 86)
Affinity DataKi:  0.950nM ΔG°:  -53.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148156(US8962612, 28)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148154(US8962612, 23)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148167(US8962612, 78)
Affinity DataKi:  1.30nM ΔG°:  -52.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148164(US8962612, 69)
Affinity DataKi:  1.60nM ΔG°:  -52.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148162(US8962612, 62)
Affinity DataKi:  1.90nM ΔG°:  -51.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148161(US8962612, 61)
Affinity DataKi:  2.5nM ΔG°:  -51.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148157(US8962612, 44)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148166(US8962612, 76)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148153(US8962612, 8)
Affinity DataKi:  3.60nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148168(US8962612, 79)
Affinity DataKi:  3.70nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148160(US8962612, 60)
Affinity DataKi:  3.90nM ΔG°:  -49.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148170(US8962612, 81)
Affinity DataKi:  4.20nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148152(US8962612, 4)
Affinity DataKi:  4.30nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148159(US8962612, 49)
Affinity DataKi:  6.60nM ΔG°:  -48.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148158(US8962612, 46)
Affinity DataKi:  6.90nM ΔG°:  -48.5kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590536(CHEMBL5209329)
Affinity DataIC50:  70nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590537(CHEMBL5205152)
Affinity DataIC50:  77nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590541(CHEMBL5181467)
Affinity DataIC50:  130nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590532(CHEMBL5208546)
Affinity DataIC50:  160nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590543(CHEMBL5186010)
Affinity DataIC50:  260nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590542(CHEMBL5191000)
Affinity DataIC50:  340nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590533(CHEMBL5204061)
Affinity DataIC50:  350nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590545(CHEMBL5206689)
Affinity DataIC50:  370nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590530(CHEMBL5196734)
Affinity DataIC50:  470nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590546(CHEMBL5177793)
Affinity DataIC50:  650nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590544(CHEMBL5196761)
Affinity DataIC50:  770nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590538(CHEMBL5181293)
Affinity DataIC50:  940nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590547(CHEMBL5202742)
Affinity DataIC50:  2.10E+3nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590531(CHEMBL5199429)
Affinity DataIC50:  3.00E+3nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590539(CHEMBL5187482)
Affinity DataIC50:  3.20E+3nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590540(CHEMBL5193630)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590534(CHEMBL5208763)
Affinity DataIC50:  1.80E+4nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetGTPase KRas(Homo sapiens (Human))
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50590535(CHEMBL5170321)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed